Item 7.01 Regulation FD Disclosure. On September 26, 2025, Meiji Holdings Co., Ltd. announced that its subsidiary, Meiji Seika Pharma Co., Ltd. (“ Meiji”), announced today that it launched a new presentation of KOSTAIVE®, a self-amplifying mRNA vaccine against COVID-19. The product targets the SARS-CoV-2 Omicron sub lineage JN.1 variant XEC. In non-clinical studies, it induced neutralizing antibodies not only against Omicron JN.1 and XEC, but also against LP.8.1 and the currently circulating variants XFG and NB.1.8.1. The formulation is supplied as a two-dose vial, with one vial per carton. As previously announced on April 11, 2023, Meiji entered into a distribution agreement with Seqirus, Inc. (“ CSL Seqirus”), a part of CSL Limited, and one of the world’s leading influenza vaccine providers, for the distribution and sales of Arcturus Therapeutics Holdings Inc.’s (the “ Company” or “ Arcturus”) self-amplifying mRNA vaccine candidate against COVID-19 in Japan. A copy of Meiji’s press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information set forth in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchang e Act”), or otherwise subject to the liabilities of that Section. The information in this Item 7.01 shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing. Cautionary Note Regarding Forward-Looking Statements

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated September 26, 2025 ─────────────────────────────────────────────────────────── SIGNATURES